An Extension Study of S-606001 in Participants With Late-onset Pompe Disease (LOPD)

The primary purpose of this study is to evaluate the long-term safety and tolerability profile of S-606001 in participants with LOPD. Participants who completed other S-606001 studies (for example, NCT07123155), including participants in a S-606001 study whose allocated arm was terminated by the sponsor and who are willing to participate in this study, will be enrolled globally.

NCT Number	NCT07750990
Lead Sponsor	Shionogi
Conditions	Pompe Disease
Enrollment	60 participants
Start Date	2026-08-31
Primary Completion	2028-08-31 (estimated)
Study Completion	2028-08-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-06